Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biol Direct ; 17(1): 1, 2022 01 06.
Artículo en Inglés | MEDLINE | ID: mdl-34991683

RESUMEN

BACKGROUND: Long non-coding RNAs (lncRNAs) have been reported to be vital factors to affect the expression of genes and proteins. Also, it has been proved that the abnormal expression or mutation of lncRNAs stands as a signal of metastasis and proliferation of cancer. Nevertheless, the majority of lncRNAs still need to be explored in abundant cancers especially in oral squamous cell carcinoma (OSCC). METHODS: RT-qPCR assays were applied to test the expression of RNAs. Mechanism assays were performed to verify the combination among NORAD, TPM4 and miR-577. Also, functional assays were conducted to verify the function of RNAs on OSCC cells. RESULTS: LncRNA NORAD was highly expressed in OSCC tissues and cells. NORAD silencing repressed the biological behaviors of OSCC cells. MiR-577 was found in OSCC with low expression, and RIP assays illustrated that NORAD, miR-577 and TPM4 coexisted in RNA-induced silencing complexes. Rescue assays proved that the overexpression of TPM4 could recover the effect of NORAD silencing on OSCC progression. CONCLUSIONS: It was revealed that NORAD functioned as a tumor promoter to sponge miR-577 thus elevating TPM4 in OSCC, which indicated that NORAD was worthy to be studied as a target for the treatment of OSCC.


Asunto(s)
Carcinoma de Células Escamosas , Neoplasias de Cabeza y Cuello , MicroARNs , Neoplasias de la Boca , ARN Largo no Codificante , Carcinoma de Células Escamosas/genética , Línea Celular Tumoral , Proliferación Celular/genética , Regulación Neoplásica de la Expresión Génica , Neoplasias de Cabeza y Cuello/genética , Humanos , MicroARNs/genética , MicroARNs/metabolismo , Neoplasias de la Boca/genética , Neoplasias de la Boca/patología , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Tropomiosina/genética , Tropomiosina/metabolismo , Tropomiosina/farmacología
2.
Med Sci Monit ; 27: e931544, 2021 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-34428195

RESUMEN

BACKGROUND This study explored the clinical effects of whole-process digitalization (WD)-assisted immediate implant placement (IIP) and immediate restoration (IR) in the aesthetic zone and clarified the clinical procedures. MATERIAL AND METHODS Patients who received maxillary aesthetic region IIP and IR treatment were randomly distributed into WD-assisted and conventional groups. Postoperative assessment included implant accuracy, marginal bone loss, aesthetic evaluation, and patient satisfaction evaluation. The aesthetic evaluation included visual analog score (VAS), pink aesthetic score (PES), and white aesthetic score (WES). Numerical data, measurement data, and grade data were analyzed by χ² test, t test, and Mann-Whitney U test. RESULTS The WD-assisted group exhibited decreased implant accuracy, including coronal deviation, apical deviation, angular deviation, and depth deviation, compared with the conventional group (P<0.05). The marginal bone loss in both the mesiodistal direction and the buccolingual direction were significantly lower in the WD-assisted group than in the conventional group (P<0.05). The VAS, PES, and WES were all significantly higher in the WD-assisted group than in the conventional group at 3, 6, and 12 months after surgery (P<0.05). Patients in the WD-assisted group also reported a higher satisfaction level than those in the conventional group (P<0.05). CONCLUSIONS WD-assisted IIP and IR treatment in the aesthetic zone increased implant accuracy, decreased marginal bone loss, improved aesthetic effect, and increased patient satisfaction compared with conventional treatment. Therefore, WD-assisted IIP and IR treatment constitutes a promising approach in clinical oral implantology.


Asunto(s)
Implantación Dental/métodos , Implantación Dental/normas , Implantes Dentales , Estética Dental , Adulto , Femenino , Humanos , Imagenología Tridimensional , Masculino , Maxilar/cirugía , Satisfacción del Paciente , Radiografía , Cirugía Asistida por Computador/métodos , Cirugía Asistida por Computador/normas , Factores de Tiempo , Resultado del Tratamiento
3.
Int J Clin Exp Pathol ; 8(5): 4367-77, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26191128

RESUMEN

Icariside II (ICS II) is a prenylated active flavonol from the roots of epimedium koreanum Nakai, and has many biological activities, including anti-osteoporosis, anti-hypoxia and anti-cancer activities. In this study, we aimed to study the effect of ICS II on osteogenic differentiation of bone marrow derived stromal cells (BMSCs). Cell surface markers of cultured BMSCs were analyzed by flow cytometry and identified by multi-lineage differentiation assays. BMSCs proliferation was determined by the cell counting kit-8 (CCK-8) assay for 2, 4, 6 and 8 days in a range of ICS II concentrations. The osteogenic response of BMSCs to ICS II in vitro was examined by alkaline phosphatase (ALP) activity assay and Alizarin red staining on calcium nodule formation. Results showed ICS II significantly improved ALP activity, and calcium deposition. The optimal concentration of ICS II for enhancing osteogenic differentiation of BMSCs was 10(-5). Therefore, we concluded ICS II can enhance the osteogenic differentiation of BMSCs which may be useful in clinic.


Asunto(s)
Células de la Médula Ósea/citología , Diferenciación Celular/efectos de los fármacos , Flavonoides/farmacología , Células Madre Mesenquimatosas/citología , Osteogénesis/efectos de los fármacos , Animales , Células de la Médula Ósea/efectos de los fármacos , Células Cultivadas , Perros , Citometría de Flujo , Células Madre Mesenquimatosas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA